Skip to main content

Insulin Aspart Injection Shortage

Last Updated: May 20, 2024
Status: Current

Products Affected - Description
    • Fiasp Flextouch subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3204-15
Reason for the Shortage
    • Novo Nordisk states the shortage is due to increased demand. The company did not provide availability information on Relion products.
Available Products
    • Fiasp subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 00169-3201-11
    • Fiasp Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3205-15
    • Insulin Aspart Flexpen subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 73070-0103-15
    • Insulin Aspart Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 73070-0102-15
    • Novolog subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 00169-7501-11
    • Novolog Flexpen subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-6339-10
    • Novolog Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3303-12
    • Insulin Aspart subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 73070-0100-11

Estimated Resupply Dates

    • Novo Nordisk has Fiasp Flextouch 3 mL pens on back order and the company estimates a release date in July 2024.

Updated

Updated May 20, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 10, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.